Cargando…

Assessment of circulating biomarkers for potential pharmacodynamic utility in patients with lymphoma

PURPOSE: Treatment efficacy and toxicity are difficult to predict in lymphoma patients. In this study, the utility of circulating biomarkers in predicting and/or monitoring treatment efficacy/toxicity were investigated. PATIENTS AND METHODS: Circulating biomarkers of cell death (nucleosomal DNA (nDN...

Descripción completa

Detalles Bibliográficos
Autores principales:	Greystoke, A, O'Connor, J P B, Linton, K, Taylor, M B, Cummings, J, Ward, T, Maders, F, Hughes, A, Ranson, M, Illidge, T M, Radford, J, Dive, C
Formato:	Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2011
Materias:	Molecular Diagnostics
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3049589/ https://www.ncbi.nlm.nih.gov/pubmed/21245866 http://dx.doi.org/10.1038/sj.bjc.6606082

Ejemplares similares

Multi-level evidence that circulating CK18 is a biomarker of tumour burden in colorectal cancer
por: Greystoke, A, et al.
Publicado: (2012)

Issues on fit-for-purpose validation of a panel of ELISAs for application as biomarkers in clinical trials of anti-Angiogenic drugs
por: Brookes, K, et al.
Publicado: (2010)

A study to investigate dose escalation of doxorubicin in ABVD chemotherapy for Hodgkin lymphoma incorporating biomarkers of response and toxicity
por: Gibb, A, et al.
Publicado: (2013)

DCE-MRI biomarkers of tumour heterogeneity predict CRC liver metastasis shrinkage following bevacizumab and FOLFOX-6
por: O'Connor, J P B, et al.
Publicado: (2011)

A pilot study to explore circulating tumour cells in pancreatic cancer as a novel biomarker
por: Khoja, L, et al.
Publicado: (2012)

Detection of BRAF mutations in the tumour and serum of patients enrolled in the AZD6244 (ARRY-142886) advanced melanoma phase II study
por: Board, R E, et al.
Publicado: (2009)

Prognostic utility of pre-operative circulating osteopontin, carbonic anhydrase IX and CRP in renal cell carcinoma
por: Sim, S H, et al.
Publicado: (2012)

Automated prognostic pattern detection shows favourable diffuse pattern of FOXP3(+) Tregs in follicular lymphoma
por: Nelson, Lilli S, et al.
Publicado: (2015)

Systematic analysis of circulating soluble angiogenesis-associated proteins in ICON7 identifies Tie2 as a biomarker of vascular progression on bevacizumab
por: Zhou, Cong, et al.
Publicado: (2016)

The utility of urine-circulating miRNAs for detection of prostate cancer
por: Stuopelyte, Kristina, et al.
Publicado: (2016)

Acquisition of biologically relevant gene expression data by Affymetrix microarray analysis of archival formalin-fixed paraffin-embedded tumours
por: Linton, K M, et al.
Publicado: (2008)

Serum protein profiling reveals baseline and pharmacodynamic biomarker signatures associated with clinical outcome in mCRC patients treated with chemotherapy ± cediranib
por: Pommier, A J C, et al.
Publicado: (2014)

Circulating galectins -2, -4 and -8 in cancer patients make important contributions to the increased circulation of several cytokines and chemokines that promote angiogenesis and metastasis
por: Chen, C, et al.
Publicado: (2014)

Detection of HER2 amplification in circulating free DNA in patients with breast cancer
por: Page, K, et al.
Publicado: (2011)

Circulating insulin-like growth factor axis and the risk of pancreatic cancer in four prospective cohorts
por: Wolpin, B M, et al.
Publicado: (2007)

The presence of disseminated tumour cells in the bone marrow is inversely related to circulating free DNA in plasma in breast cancer dormancy
por: Payne, R E, et al.
Publicado: (2012)

Comparison of bone marrow, disseminated tumour cells and blood-circulating tumour cells in breast cancer patients after primary treatment
por: Slade, M J, et al.
Publicado: (2009)

Considerations for the use of plasma cytokeratin 18 as a biomarker in pancreatic cancer
por: Dive, C, et al.
Publicado: (2010)

Circulating fibrinogen is a prognostic and predictive biomarker in malignant pleural mesothelioma
por: Ghanim, B, et al.
Publicado: (2014)

Bcl-2 expression in rituximab refractory cutaneous B-cell lymphoma
por: Wobser, M, et al.
Publicado: (2007)

Circulating tumour cells as a biomarker for diagnosis and staging in pancreatic cancer
por: Ankeny, J S, et al.
Publicado: (2016)

Levels of a subpopulation of platelets, but not circulating endothelial cells, predict early treatment failure in prostate cancer patients after prostatectomy
por: Wong, C K E, et al.
Publicado: (2012)

Changes in circulating microRNA levels associated with prostate cancer
por: Bryant, R J, et al.
Publicado: (2012)

Neuroendocrine and epithelial phenotypes in small-cell lung cancer: implications for metastasis and survival in patients
por: Stovold, R, et al.
Publicado: (2013)

Cellular senescence induced by aberrant MAD2 levels impacts on paclitaxel responsiveness in vitro
por: Prencipe, M, et al.
Publicado: (2009)

Circulating tumour cells in the central and the peripheral venous compartment in patients with metastatic breast cancer
por: Peeters, D J E, et al.
Publicado: (2011)

Clinical significance of CDX2-positive circulating tumour cells in colorectal cancer patients
por: Wong, S C C, et al.
Publicado: (2011)

Identification of circulating microRNAs as diagnostic biomarkers for use in multiple myeloma
por: Jones, C I, et al.
Publicado: (2012)

Activated c-SRC in ductal carcinoma in situ correlates with high tumour grade, high proliferation and HER2 positivity
por: Wilson, G R, et al.
Publicado: (2006)

Detection and prognostic significance of circulating tumour cells in patients with metastatic breast cancer according to immunohistochemical subtypes
por: Peeters, D J E, et al.
Publicado: (2014)

Circulating biomarkers for detection of ovarian cancer and predicting cancer outcomes
por: Shapira, I, et al.
Publicado: (2014)

Increased mobilisation of circulating endothelial progenitors in von Hippel-Lindau disease and renal cell carcinoma
por: Bhatt, R S, et al.
Publicado: (2011)

Prognostic value of circulating tumour cells for early recurrence after resection of colorectal liver metastases
por: Lalmahomed, Z S, et al.
Publicado: (2015)

Detection of circulating tumour cells in peripheral blood with an automated scanning fluorescence microscope
por: Ntouroupi, T G, et al.
Publicado: (2008)

Validation of histomolecular classification utilizing histological subtype, MUC1, and CDX2 for prognostication of resected ampullary adenocarcinoma
por: Schueneman, A, et al.
Publicado: (2015)

A multimarker QPCR-based platform for the detection of circulating tumour cells in patients with early-stage breast cancer
por: Molloy, T J, et al.
Publicado: (2011)

Circulating cell-free miRNAs as biomarker for triple-negative breast cancer
por: Shin, V Y, et al.
Publicado: (2015)

Clinical value of circulating endothelial cells and of soluble CD146 levels in patients undergoing surgery for non-small cell lung cancer
por: Ilie, M, et al.
Publicado: (2014)

Analysis of circulating angiogenic biomarkers from patients in two phase III trials in lung cancer of chemotherapy alone or chemotherapy and thalidomide
por: Young, R J, et al.
Publicado: (2012)

Circulating sphingosine-1-phosphate and erythrocyte sphingosine kinase-1 activity as novel biomarkers for early prostate cancer detection
por: Nunes, J, et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_7nc30sl99oh20v5047hhk1unah